Literature DB >> 12605662

Acquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman's disease: a case report.

Marco Marietta1, Samantha Pozzi, Mario Luppi, Marcello Bertesi, Cinzia Cappi, Monica Morselli, Giuseppe Torelli.   

Abstract

Multicentric Castleman's Disease (MCD) is an atypical lymphoproliferative disorder, related to human herpesvirus 8 (HHV-8) infection and often associated with autoimmune diseases such as haemolytic anaemia and thrombocytopenia. Acquired haemophilia (AH) is a rare, life-threatening disease, which can occur in association with lymphoproliferative disorders, although only one case of AH in MCD has been described so far. We report the case of a human immuno deficiency virus negative 71-yr-old woman referred to our hospital for prolonged bleeding on surgical site following a lymph node biopsy. Lymph node histology revealed MCD, while the screening for the bleeding disorder showed prolonged activated partial thromboplastin time (APTT) (ratio: 1.89, normal value <1.24), low factor VIII (FVIII:C) levels (6%) with anti-factor VIII antibodies (2.3 Bethesda units), leading to a diagnosis of AH. Virological studies on plasma, lymphocyte and bronchoalveolar wash showed positivity for HHV-8 infection. Treatment with steroids (metilprednisolone 1-1.5 mg/kg/d) and cyclophosphamide (100 mg/d orally) was unsuccessful, and then antiviral therapy with cidofovir (5 mg/kg/wk) was started. A transient normalisation of APTT was seen after two administrations of cidofovir, but then coagulation parameters worsened and a large haematoma of the arm appeared. Bleeding was successfully stopped with two boluses of recombinant activated factor VII (Novoseven 90 microg/kg). Therapy with anti-CD 20 monoclonal antibody rituximab (Mabthera 375 mg/m2 once a week for 4 wk) was started, and following two administrations APTT normalised once again. Cardiological and neurological complications arose before the third dose of rituximab and the patient died shortly afterwards.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605662     DOI: 10.1034/j.1600-0609.2003.00038.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  7 in total

1.  HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.

Authors:  Paolo Nicoli; Ubaldo Familiari; Marco Bosa; Tiziano Allice; Francesca Mete; Alessandro Morotti; Daniela Cilloni; Giuseppe Saglio; Angelo Guerrasio
Journal:  Int J Hematol       Date:  2009-09-12       Impact factor: 2.490

Review 2.  Rituximab for eradicating inhibitors in people with acquired haemophilia A.

Authors:  Tracey Remmington; Sherie Smith
Journal:  Cochrane Database Syst Rev       Date:  2021-08-23

Review 3.  The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A.

Authors:  Giovanni D'arena; Elvira Grandone; Matteo N D Di Minno; Pellegrino Musto; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2015-09-03       Impact factor: 3.443

Review 4.  Treatment of Castleman's disease.

Authors:  Angela Dispenzieri; Morie A Gertz
Journal:  Curr Treat Options Oncol       Date:  2005-05

Review 5.  Update and new approaches in the treatment of Castleman disease.

Authors:  Kah-Lok Chan; Stephen Lade; H Miles Prince; Simon J Harrison
Journal:  J Blood Med       Date:  2016-08-03

6.  Multicentric Castleman's Disease, Associated with Idiopathic Thrombocytopenic Purpura.

Authors:  Ruchi Sood; Harris C Taylor; Hamed Daw
Journal:  Case Rep Hematol       Date:  2013-10-02

Review 7.  TAFRO Syndrome with Renal Thrombotic Microangiopathy: Insights into the Molecular Mechanism and Treatment Opportunities.

Authors:  Kun-Hua Tu; Pei-Yi Fan; Tai-Di Chen; Wen-Yu Chuang; Chao-Yi Wu; Cheng-Lung Ku; Ya-Chung Tian; Chih-Wei Yang; Ji-Tseng Fang; Huang-Yu Yang
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.